Gastroenterology
Volume 137, Issue 5 , Pages 1628-1640 , November 2009

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

  • Konstantinos Karmiris

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Gilles Paintaud

      Affiliations

    • Laboratory of Pharmacology-Toxicology, Tours University Hospital, Tours, France
    • ,
  • Maja Noman

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Charlotte Magdelaine–Beuzelin

      Affiliations

    • Laboratory of Immunology, Tours University Hospital, Tours, France
    • ,
  • Marc Ferrante

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Danielle Degenne

      Affiliations

    • Laboratory of Immunology, Tours University Hospital, Tours, France
    • ,
  • Karolien Claes

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Tamara Coopman

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Nele Van Schuerbeek

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Gert Van Assche

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Severine Vermeire

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Paul Rutgeerts

      Affiliations

    • Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    • Corresponding Author InformationReprint requests Address requests for reprints to: Paul Rutgeerts, MD, PhD, Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B-3000, Leuven, Belgium. fax: (32) 16 34 44 19

Received 13 October 2008 ,Accepted 23 July 2009.

References 

  1. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? (Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)). Gut. 1996;39:690–697
  2. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657
  3. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148–1157
  4. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease (Crohn's Disease cA2 Study Group). N Engl J Med. 1997;337:1029–1035
  5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359:1541–1549
  6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876–885
  7. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single center cohort. Gut. 2009;58:492–500
  8. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppresion in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861–1868
  9. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917–924
  10. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601–608
  11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542–553
  12. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451–1459
  13. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248–1254
  14. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333
  15. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–65
  16. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239
  17. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. Ann Intern Med. 2007;146:829–838
  18. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–926
  19. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122–1126
  20. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A
  21. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169–174
  22. Hinojosa J, Gomollon F, Garcia S, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther. 2007;25:409–418
  23. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label therapy. Aliment Pharmacol Ther. 2007;25:675–680
  24. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 2007;25:787–796
  25. Ho GT, Smith L, Aitken S, et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther. 2008;27:308–315
  26. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31
  27. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849–853
  28. Fidder HH, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-center cohort study. Gut. 2009;58:501–508

 This article has an accompanying continuing medical education activity on page 1836. Learning Objective: Upon completion of this examination, successful learners will be able to interpret the role of immunogenicity in the use of biologic agents in inflammatory bowel diseases.

 Conflicts of interest The authors disclose the following: Dr Paintaud is on an advisory committee for Roche, has a research contract with Innate Pharma, is a consultant for LFB, and receives a speaker fee from Pierre Fabre; Dr Van Assche receives a speaker fee/research support from Centocor, Schering-Plough, Abbott, and UCB; Dr Vermeire receives grants/research support from UCB; is a consultant for AstraZeneca, Ferring, and Pfizer; is on the speakers bureau for Schering-Plough, Abbott, Ferring, and UCB; and is on an advisory committee for Shire and Ferring; and Dr Rutgeerts receives research grants, lecture fees, and consultant fees from Abbott, Centocor, Schering-Plough, and UCB. The remaining authors disclose no conflicts.

 Funding Supported by a grant from European Crohn's and Colitis Organisation and the Hellenic Society of Gastroenterology.

PII: S0016-5085(09)01387-0

doi: 10.1053/j.gastro.2009.07.062

Gastroenterology
Volume 137, Issue 5 , Pages 1628-1640 , November 2009

Article Tools

* Image Usage & Resolution